Beam Therapeutics

Beam Therapeutics

Beam Therapeutics

Beam Therapeutics is pioneering the use of CRISPR base editing to develop precision genetic medicines that treat disease.
Founded
2017
Raised
$402M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$180,000,000
IPO - 2020
Team Size
1–10
Employees
Pulse 2.0

Beam Therapeutics (BEAM) Stock: Why It Fell Over 3% Today

MedCity News

FDA hits pause on Beam Therapeutics’ off-the-shelf cell therapy for blood cancers

GeekWire

Sana Biotechnology inks $50M deal for precise gene editing system from Beam Therapeutics

$180,000,000 IPO
MedCity News

Beam Therapeutics raises $180M in IPO

Xconomy

Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered

MedCity News

Gene editing company Beam Therapeutics aims for $100M IPO

Xconomy

Beam Therapeutics Preps IPO and Sheds Light on Its Gene-Editing Drugs

$135,000,000 Venture capital (Series B)
FinSMEs

Beam Therapeutics Secures $135M in Series B Financing

Xconomy

Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M

Science
$87,000,000 Venture capital (Series A)
FinSMEs , PE HUB , MedCity News

Beam Therapeutics Raises up to $87M in Series A Financing

Science Education